The double-edged sword of statin immunomodulation

International Journal of Cardiology

Volumn 135, Issue 1, 2009, Pages 128-130

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^c  

^a Fountain Medical Court ^*  (United States)

^b Servizio Sanitario ^*  (Italy)

^c Ospedale Civile di Tolmezzo   (Italy)

Author keywords

Cancer; Infectious diseases; Neurodegenerative disorders; Statins; Tregs

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENICILLIN G; PRAVASTATIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; HEPATITIS B VIRUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOMODULATION; LATENT VIRUS INFECTION; NEUROPROTECTION; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; VARICELLA ZOSTER VIRUS;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; INFECTION; NEOPLASMS; NEURODEGENERATIVE DISEASES; RISK FACTORS; T-LYMPHOCYTES, REGULATORY;

EID: 67349193977     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.01.023     Document Type: Article

References (31)

1. Rallidis L.S., Lekakis J., and Kremastinos D.T. Current questions regarding the use of statins in patients with coronary heart disease. Int J Cardiol 122 (2007) 188-194
2. O'Keefe Jr. J.H., Cordain L., Harris W.H., Moe R.M., and Vogel R. Optimal low-density protein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 43 (2004) 2142-2146
3. Alsheikh A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 (2007) 409-418
4. Mausner-Fainberg K., Luboshits G., Mor A., et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 197 (2008) 829-839
5. Mallat Z., Ait-Oufella H., and Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 16 (2005) 518-524
6. Yakirevich E., and Resnick M.B. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 25 (2007) 2506-2508
7. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 (2007) 1167-1174
8. Bates G.J., Fox S.B., Han C., et al. Quantification or regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 (2006) 5373-5380
9. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
10. Kobayashi N., Nobuyoshi H., Yamagami W., et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13 (2007) 902-911
11. The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
12. West of Scotland Coronary Prevention-Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 (2007) 1477-1486
13. Miller A.M., Lundberg K., Ozenci V., et al. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177 (2006) 7398-7405
14. Gruver A.L., Hudson L.L., and Sempowski G.D. Immunosenescence of ageing. J Pathol 211 (2007) 144-156
15. The PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
16. The LIPID Investigators. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 134 (2001) 931-940
17. The Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years or older with stable coronary heart disease. Ann Intern Med 147 (2007) 1-9
18. Hoffmann P., Roumeguere T., and van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355 (2006) 2705-2707
19. Edwards I.R., Star K., and Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from Vigibase. Drug Saf 30 (2007) 515-525
20. Pacheco R., Gallart T., Lluis C., and Franco R. Role of glutamate on T-cell mediated immunity. J Neuroimmuno 185 (2007) 9-19
21. Kipnis J., Yoles E., Mizrahi T., Ben-Nur A., and Schwartz M. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. J Neuroimmuno 130 (2002) 78-85
22. Kipnis J., Mizrahi T., Hauben E., et al. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. PNAS 99 (2002) 15620-15625
23. Belkaid Y., and Rouse B. Natural regulatory T cells in infectious disease. Nat Immunol 6 (2005) 353-360
24. Rouse B.T., and Suvas S. Regulatory cells and infectious agents: detentes cordiale and contraire. J Immunol 173 (2004) 2211-2215
25. Aandahl E.M., Michaelsson J., Moretto W.J., Hecht F.M., and Nixon D.F. Human CD4+CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78 (2004) 2454-2459
26. Kitner A., McNally J., Riggin L., et al. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. PNAS 104 (2007) 3390-3395
27. Stoop J.N., van der Molen R.G., Baan C.C., et al. Regulatory T-cells contribute to the impaired immune response in patients with chronic hepatitis B viral infection. Hepatology 41 (2005) 771-778
28. Cabrera R., Tu Z., Xu Y., et al. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 (2004) 1062-1071
29. Yawn B.P., Saddier P., Wollan P.C., et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82 (2007) 1341-1349
30. Lipitor prescribing information, Table 8, http://www.pfizer.com/files/products/uspi_lipitor.pdf (Accessed November 18, 2007).
31. Roberts W.C. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 78 (1996) 377-378